Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$15.41M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): 0.3
• Beta (1Y): -1.31
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: C$0.09 ▲(17.50% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is held down primarily by weak financial performance—negative operating/free cash flow and volatile, low-quality earnings signals—despite a recently improved balance sheet. Technicals provide some support due to a positive trend and MACD, but elevated RSI suggests stretched momentum. Valuation contributes modestly negative impact because the negative P/E limits interpretability and no dividend yield is available.

Positive Factors

Low current debt

A materially lower absolute debt load and a low current debt-to-equity position materially reduce near-term refinancing and interest-rate risk. For a biotech, this increases strategic optionality for R&D funding or partnerships without immediate solvency pressure, improving medium-term durability.

Balance-sheet repair trend

Demonstrated improvement in leverage over multiple periods signals management has taken steps to restore financial stability. A repaired balance sheet strengthens credibility with partners and investors, lowering the probability of distress financing and enabling more consistent long-term investment in programs.

Occasional positive operating cash flow history

Historic episodes of positive operating cash flow indicate the underlying operations can generate cash under certain conditions. That operational potential, combined with a stronger balance sheet, means the company has a plausible path back to sustainable cash generation if execution stabilizes.

Negative Factors

Persistent cash burn

Meaningful negative operating and free cash flow across the trailing twelve months creates a structural funding requirement. For a biotech, ongoing cash burn typically necessitates additional financing or dilution, raising the risk that R&D timelines and strategic plans are constrained by capital availability.

Volatile, low-quality revenue and earnings

Negative TTM revenue and profitability driven by non-operating items indicate core commercial traction is inconsistent. Structural reliance on one-offs undermines forecastability of cash flow and margins, complicating long-term planning and making sustained value creation dependent on operational improvements.

History of heavy leverage and negative equity

A track record that includes very high leverage and past negative equity weakens stakeholder confidence and can leave legacy covenant or financing constraints. Even with recent repair, historical capital-structure stress raises the long-term risk profile and reduces resilience to future shocks.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Financial profile remains high-risk. Income statement quality is weak with volatile/negative TTM revenue and profitability that appears driven by non-operating items, while cash flow is meaningfully negative (operating cash flow and free cash flow), indicating ongoing cash burn. The balance sheet has improved with very low current debt versus equity, but prior periods of heavy leverage and negative equity add durability risk.

Income Statement

Results are volatile. TTM (Trailing-Twelve-Months) revenue is negative (-$4.33M) despite a very large reported growth rate, which raises quality-of-revenue concerns. Profitability is mixed: TTM shows a large positive net income ($20.49M), but margins are inconsistent (net margin negative while EBIT/EBITDA margins are positive), and the annual history includes sizable losses (e.g., 2022 and 2024) alongside profitable years (2023). Overall, earnings appear driven by non-operating items and/or one-offs rather than steady operating performance.

Balance Sheet

Leverage has improved materially over time. TTM total debt is very low ($0.18M) versus equity ($17.23M), and the latest debt-to-equity is modest, indicating balance sheet repair. However, the track record shows prior periods of heavy leverage (debt-to-equity near ~3–4x in 2022–2024) and even negative equity in 2021, highlighting historical balance sheet stress. Returns on equity are currently strong (TTM ROE ~1.82), but given earnings volatility, the sustainability of returns is a key risk.

Cash Flow

Cash generation is currently weak. TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both meaningfully negative (about -$4.10M), and free cash flow growth is also negative, pointing to rising cash burn. While some earlier years produced positive operating cash flow (notably 2022–2024), the latest shift back to outflows suggests the business may require continued financing to fund operations, which increases dilution or funding risk for a biotechnology company.

Breakdown	TTM	Mar 2025	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	-4.33M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-3.01M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.96M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	20.49M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	22.06M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	15.89M	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	183.11K	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	4.83M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	17.23M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-4.10M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-4.10M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	6.31M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.36M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.60 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$15.41M	0.30	―	―	-3.93%	-575.24%
HEM	44 Neutral	C$13.67M	-7.36	―	―	―	-24.89%
GLOW	41 Neutral	C$9.06M	-20.15	-95.68%	―	239.98%	39.01%